Thymosin Alpha-1 Research Notes
Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for Thymosin Alpha-1. Research use only.
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.
The selected Thymosin Alpha-1 records cover protein interaction, in-vitro lymphocyte transcription, and a preclinical liver-cancer model.
Questions covered by the selected literature
- Which Galectin-1 interaction was measured
- How human lymphocytes responded in vitro
- Why a preclinical disease model cannot establish a general product outcome
Evidence limits
The studies use biochemical, in-vitro, or preclinical systems. They do not provide a human-use purpose for the BioPep USA research item.
A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.
Selected PubMed sources
- Thymosin α1 interacts with Galectin-1 modulating the β-galactosides affinity and inducing alteration in the biological activity.. Int Immunopharmacol. 2023 May. PMID: 37028279.
- Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1.. Ann N Y Acad Sci. 2010 Apr. PMID: 20536445.
- IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.. J Gastroenterol Hepatol. 2026 May. PMID: 41883056.
BioPep USA record
BioPep USA currently lists Thymosin Alpha-1. Use the product page for current options and the documentation page for lot records.
Last reviewed: July 20, 2026.
